Breaking News

Hovione, Merrion Enter Strategic GIPET Tech Pact

July 15, 2014

Will use Merrion’s GIPET technology to manufacture clinical and commercial products

Hovione and Merrion Pharmaceuticals have entered a strategic partnership for the use of Merrion’s GIPET absorption enhancing technology by Hovione clients. The companies have established a relationship on technical issues relating to GIPET manufacture and will collaborate on the feasibility assessment of GIPET with development compounds introduced by third parties. Hovione will leverage its international manufacturing capability to supply new products from clinical trials to commercialization.
Merrion’s chief executive officer, Dr. John Fox, said, “I am delighted that Merrion Pharmaceuticals is working with a partner of such scale and reputation. Merrion and Hovione represent complementary offerings to companies seeking to develop tablet versions of compounds that otherwise may have been administered by injection or never reached patients at all.”
“We are very pleased to announce this collaboration with Merrion Pharmaceuticals, which extends our current expertise and capabilities in improving solubility of oral drugs by addressing the permeability limitations of BCS classes III and IV drugs. This adds value to our customers and benefits the patients. This agreement reinforces our strategy of combining strengths with other innovative companies like Merrion, to create better medicines,” said Dave Hoffman, Hovione’s vice president of sales and business development.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research